Browsing: Unprecedented

Unprecedented Milestone in Human Pharmaceutical History: One Target, Two Blockbuster Drugs, $100 Billion Annual Revenue

By 0

On August 5, Eli Lilly released its 2026 first-half performance report. One number took the entire pharmaceutical industry’s breath away: Tirzepatide — the glycemia-lowering version Mounjaro and the weight-loss version Zepbound — posted combined revenue of 27.693 billion US dollars in the first half of the year, representing an 88% year-on-year increase